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TITLE OF CASE  
 
Upper gastrointestinal haemorrhage associated with cholinesterase inhibitor use 
 
SUMMARY  
 
An 86 year old man was admitted with a 3 day history of melaena and syncope. He was 
haemodynamically compromised and anaemic on presentation. His only past medical history 
was mild Alzheimer’s Disease diagnosed 6 months prior. For this, he was on donepezil, a 
cholinesterase inhibitor (ChEI), with a recent dose increase 3 months ago. After fluid 
resuscitation with packed red cells, an endoscopy was performed which showed an acute 
duodenal ulcer. This was treated with high dose proton pump inhibitor. He recovered well and 
was discharged on donepezil. In view of other absent risk factors of upper gastrointestinal 
haemorrhage, donepezil was the likely causative agent. ChEIs is associated with frequent side 
effects and increased hospitalisation due to central and peripheral increase in acetylcholine. 
With this case report, we review the literature of side effects related to ChEIs, where the 
mechanisms of action, complications and appropriate management are discussed. 
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BACKGROUND  
 
The National Institute of Clinical Excellence (NICE) of United Kingdom recommends the use of 
cholinesterase inhibitors (ChEIs) as a pharmacological agent in the multipronged approach in 
managing Alzheimer’s Disease, the most common form of dementia.[1] ChEIs are currently 
licensed for patients with mild to moderate Alzheimer’s Disease,[1] where it requires specialist 
input with regular cognitive and behavioural assessments to assess efficacy. With the incidence 
of dementia steadily rising to a projected 40% over the next 12 years,[2] coupled with improved 
diagnostics, care bundles and organisation of specialist teams, general physicians and 
practitioners would be encountering ChEIs at a greater frequency. Our case report highlights a 
patient who suffered an upper Gastrointestinal haemorrhage (UGIB) on a ChEI, donepezil, in the 
absence of any other risk factors for peptic ulcer.  
 
 
CASE PRESENTATION  
 
An 86 year old man was referred to the Acute Medicine Unit by his General Practitioner (GP) 
with a history of dark stools and dizziness on standing for three days, having had a syncopal 
episode in front of the surgery that morning. His past medical history included mild Alzheimer’s 
disease. He had started donepezil approximately five months prior to presentation, initially 
taking 5mg once a day, with the dose increased to 10mg once a day three months after. There 
was no other significant past medical or gastrointestinal disease history. Apart from donepezil, 
he was not on any other regular medication. In particular, there was no recent use of non-
steroidal anti-Inflammatory (NSAID), over-the-counter medication or alcohol consumption. He 
lived alone with help from the family.  
 
On examination, the patient’s GCS was 14/15. He was afebrile. Despite a lying blood pressure 
(BP) of 75/35, he was not tachycardic, with a regular pulse rate of 90 beats per minute. The GP 
surgery recorded a lying BP of 117/64, with an unrecordable BP on standing, indicating a 
significant postural drop. His respiratory rate was 24 breaths per minute, with oxygen 
saturations of 98% on air. His abdomen was soft, with some epigastric tenderness, but no 
rebound tenderness. Digital examination of the rectum confirmed melaena, with soft stool 
present in the rectum. 
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An erect chest radiograph showed no free air under the diaphragm. His electrocardiogram 
showed a normal sinus rhythm. His blood tests were consistent with an upper gastrointestinal 
bleed (UGIB); the haemoglobin was 75 g/L (normal values 130 – 170 g/L), urea was raised at 
21.6mmol/L (normal values 1.7 – 7.1 mmol/L), and creatinine normal. Electrolytes and liver 
enzymes were within the normal range. The patient’s Blatchford Score was 14 (Table 1). The 
case was discussed with the on-call gastroenterologist shortly after arrival, who felt that the 
most important issue was to optimise his resuscitation prior to endoscopy. He was resuscitated 
with crystalloid immediately and subsequently transfused with three units of packed red cells. 
He was haemodynamically stable overnight. His immediate post-transfusion haemoglobin was 
95g/L.  
 
At endoscopy the following morning an acute duodenal ulcer approximately 1cm in diameter 
was located in the inferior bulbar region. The Forrest Classification at time of endoscopy was IIc, 
with no blood seen in the stomach. There was no visible vessel and no active bleeding. Hence, 
no endoscopic intervention was needed.  A rapid urease test was negative, indicating 
Helicobacter pylori infection was unlikely.  
 
INVESTIGATIONS  
 
As above – blood results and gastroscopy result in Case Presentation  
 
DIFFERENTIAL DIAGNOSIS  
 
A differential diagnosis would be UGIB secondary to a uraemic gastropathy, pathology 
sometimes associated with patients with chronic kidney disease (CKD). However, we are able to 
exclude CKD as the patient’s estimated glomerular filtration rate (eGFR) was 75ml/min/1.73m2 4 
months ago. Also, he had a normal Creatinine then and on admission.   
 
Other common causes of anaemia include B12, Folate and Iron deficiency states. The patient’s 
blood results for this were normal. The thyroid function tests 6 months prior were normal. 
These are shown in Table 2. His blood count differentials did not suggest a haematological 
malignancy.  
 Revised September 2014  Page 4 of 10 
 
Common causes for an UGIB include esophageal disease such as esophagitis, perforation or UGI 
malignancy. In this case, the diagnosis was achieved by an Oesophago-gastro duodenoscopy.  
 
TREATMENT  
 
The patient was commenced on oral lansoprazole 30mg twice a day for 6 weeks.  
 
OUTCOME AND FOLLOW-UP   
 
The length of stay in hospital under the Gastroenterologists was 8 days, mainly due to a 
worsening of the patient’s mobility and cognitive function associated with the hypotensive 
shock. There was no further melaena and the haemoglobin remained stable throughout the 
admission. He was discharged on donepezil and high-dose lansoprazole.  
 
In the absence of any other identifiable cause for the development of this patient’s ulcer, we 
have reported a suspected adverse event of donepezil causing a significant UGIB through peptic 
ulceration to the Medicines and Healthcare products Regulatory Agency (MHRA). 
 
DISCUSSION  
 
Alzheimer’s Disease is the most common form of dementia, accounting for 62% of dementias in 
the UK.[2] The link between acetylcholine, cognitive decline and its role in Alzheimer’s Disease 
was greatly studied in the 1970s through animal and post-mortem brain studies.[3] This gave 
rise to ChEIs. Donepezil is a 2nd generation ChEI, where it is a selective reversible non-
competitive inhibitor of acetylcholinesterase, reducing breakdown and hence increasing levels 
of the neurotransmitter acetylcholine at the central and peripheral cholinergic synaptic clefts. 
 
A Cochrane review of mainly industry-sponsored trials has suggested that donepezil has 
significant cognitive benefits.[4] However two independent studies were unable to demonstrate 
significant clinical benefit, although either the number of participants[5] or the duration of 
treatment[6] limited these studies.  
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There are significant side effects associated with ChEI use, as shown by excess numbers of 
patients discontinuing treatment: 16-43% of patients in treatment groups versus 0-33% in 
placebo groups.[4] These side effects are mostly attributed towards unwanted cholinergic 
effects. In a Canadian population matched case-control study, the risk of hospitalisation for 
bradycardia doubled in ChEI users. In this group, ChEI was often restarted on discharge, and the 
authors felt that clinicians failed to appreciate its cardiovascular toxicity.[7] Moreover, in a 
separate cohort study, ChEI users were more likely to suffer neurocardiogenic syncope and 
syncopal related events such as hip fractures.[8] Interestingly, this cholinergic effect of 
donepezil may potentially explain why our patient did not have a compensatory tachycardia 
despite a very low systolic BP.  
 
Due to the cholinergic innervation of the GI system, the side effects of GI disturbances are 
observed among ChEI users, where nausea, vomiting and diarrhoea pre-dominate as adverse 
events.[4] The MHRA Yellow Card system has received 30 reports of gastrointestinal 
haemorrhage in patients taking donepezil, including 4 fatalities,[9] although the nature of these 
spontaneous reports means that we cannot be certain of a causal link between drug and 
suspected reaction. 38 cases of duodenal, gastric or peptic ulcers were also reported to MHRA, 
including 2 fatalities.[9] A recent retrospective population-based cohort study based on 
healthcare administrative claims databases reported on the relative frequency of UGIB in 
patients with dementia on ChEIs compared to matched nonusers.[10] More than two thirds of 
the ChEI users were on donepezil. Although no statistically significant association was found 
between UGIB and ChEI usage, it was noted that 34.4% of ChEI users were already on a gastro-
protective agent, and there was no ability to capture data such as disease severity, length of 
hospital stay or background gastrointestinal pathology. 
 
Our patient had no other risk factors for a peptic ulcer. The biological plausibility of donepezil 
causing GI ulceration could be due to its ulcer promoting effect through increased acid 
production, which is partly controlled by cholinergic vagal fibres. Only one case report has 
reported recurrent UGIB due to a gastric ulcer following ongoing donepezil use.[11] In our case, 
ulcer formation could have coincided with a recent upward dose titration of donepezil. 
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A physician has to be wary when starting patients on ChEI, where cautious administration of 
ChEIs is advised in patients who have a previous history of severe liver disease, peptic ulcer 
disease and current alcoholism. Patients were excluded from donepezil trials if they had 
‘uncontrolled gastrointestinal diseases’. Galantamine trials specifically excluded patients with 
active peptic ulcer disease and rivastigmine trials excluded patients with a peptic ulcer in the 
preceding 5 years.[4]  
 
ChEI associated side effects presents a dilemma for general physicians. Firstly, there is no 
available guidance to manage these side effects, in particular peptic ulcers. In this case the ChEI 
was continued with the addition of a gastro-protective proton pump inhibitor (PPI). However, it 
is usual for NSAIDs to be stopped after a significant UGIB. Perhaps ChEIs should be discontinued 
until ulcer healing has been confirmed. 
 
Whether there is a role for the universal use of PPI for primary prevention of ulcer formation is 
debatable. For NSAIDs, in patients who are at high risk of developing NSAID related GI adverse 
events, such as patients above the age of 65 years old, starting a PPI is recommended.[12] 
Patients placed on donepezil are likely to have a high risk factor profile towards GI disturbances. 
However, donepezil is much less widely used than NSAIDs, and the level of risk does not appear 
to be as high. We would be reluctant to recommend universal use of PPIs, given that PPIs have 
been associated with increased risk of Clostridium difficile infections and fractures.[13] Hence, a 
case-by-case approach should be adopted. 
 
Not only do we have to be vigilant about side effects, we also have to recognise the issues of 
polypharmacy and drug interactions with ChEIs in a vulnerable elderly population. This could 
prove challenging to manage. Indeed, a retrospective cohort study found that patients with 
dementia on ChEIs had an increased risk of receiving an anticholinergic drug to manage urinary 
incontinence, which would in fact oppose each other’s pharmacological action.[14]  
 
In conclusion, this case report has highlighted a significant and potentially life-threatening side 
effect of ChEIs and we have prompted discussion of their management. It is important for 
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secondary care providers and General Practitioners to have regular communications with ChEI 
users under their care and their caregivers and family members, discussing and evaluating the 
benefits and risks associated with this class of drugs at regular intervals.   
 
LEARNING POINTS/TAKE HOME MESSAGES  
 
 The usage of cholinesterase inhibitors (ChEIs) is likely to increase due to recent NICE 
recommendation and the medical communities’ higher vigilance towards an early 
diagnosis of dementia. General and acute physicians are likely to see more patients on 
ChEIs.  
 This case report exemplifies one of the potentially significant adverse events associated 
with ChEI use.  
 It is important to recognise patients that are of higher risk of developing ChEI-related 
side effects.   
 There is a need for guidance for managing ChEI-related side effects. Cessation of ChEI 
after a peptic ulcer or admission with cardiac syncope should be considered.  
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TABLES  
  
Table 1. Glasgow-Blatchford Score of patient 
 
On Admission Score  
Blood Urea (mmol/l) 
4 
21.6 
Haemoglobin (g/dl) for men  
6 
75 
Systolic Blood Pressure 
(mmHg) 3 
75 
Other markers    
Presentation with melaena 1 
Presentation with syncope 1 
Total Glasgow-Blatchford Score 15 
 
 
Table 2. Patient’s blood results on admission 
 
Investigation  
Normal 
range 
Units  result 
Ferritin 23 - 300 ug/L 136 
Vitamin B12  130 - 1100 ng/L 230 
Folate 2.7 - 15.0 ug/L 2.9 
Free T4  8 - 21 pmol/L 12 
TSH 0.35 - 3.5 mU/L 1.25 
WCC 4.0 - 10.0 109/L 10.6 
Neutrophils 2.0 - 7.0 109/L 8.87 
Lymphocytes  1.0 - 3.0 109/L 0.92 
Monocytes 0.2 - 1.0 109/L 0.76 
Eosinophils 0.02 - 0.5 109/L 0.02 
Platelets  150 - 410 109/L 173 
Globulin 21 - 35 g/L 25 
C-reactive protein 0 - 10 mg/L 2 
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PATIENT’S PERSPECTIVE  
 
Not available  
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